LT2002123A - Novel interferon for the treatment of multiple sclerosis - Google Patents

Novel interferon for the treatment of multiple sclerosis

Info

Publication number
LT2002123A
LT2002123A LT2002123A LT2002123A LT2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A
Authority
LT
Lithuania
Prior art keywords
multiple sclerosis
treatment
ifn
biologically
novel interferon
Prior art date
Application number
LT2002123A
Other languages
English (en)
Lithuanian (lt)
Inventor
Edward M. Croze
Daryl Faulds
T. Charis Wagner
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of LT2002123A publication Critical patent/LT2002123A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LT2002123A 2000-06-16 2002-12-02 Novel interferon for the treatment of multiple sclerosis LT2002123A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
LT2002123A true LT2002123A (en) 2003-06-25

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002123A LT2002123A (en) 2000-06-16 2002-12-02 Novel interferon for the treatment of multiple sclerosis

Country Status (22)

Country Link
US (1) US20020025304A1 (et)
EP (1) EP1289541A2 (et)
JP (1) JP2004505021A (et)
KR (1) KR20030009529A (et)
CN (1) CN1436086A (et)
AU (1) AU2001267099A1 (et)
BG (1) BG107370A (et)
BR (1) BR0111852A (et)
CA (1) CA2413077A1 (et)
CZ (1) CZ20024094A3 (et)
EE (1) EE200200693A (et)
HU (1) HUP0300787A2 (et)
IL (1) IL152996A0 (et)
LT (1) LT2002123A (et)
MX (1) MXPA02012308A (et)
NO (1) NO20025964L (et)
NZ (1) NZ522849A (et)
PL (1) PL359562A1 (et)
RU (1) RU2003100517A (et)
SI (1) SI21080A (et)
SK (1) SK17612002A3 (et)
WO (1) WO2001095929A2 (et)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046365A2 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1712992A1 (en) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Updating of data instructions
EP2536435B1 (en) * 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
CN116813799A (zh) 2016-02-05 2023-09-29 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
EP3577133A1 (en) 2017-02-06 2019-12-11 Orionis Biosciences NV Targeted chimeric proteins and uses thereof
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
SI9520059A (en) * 1994-05-10 1997-08-31 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis.
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
BR9815966A (pt) * 1998-05-29 2001-02-28 Biogen Inc Formulação humano de interferon beta-1a (ifn-beta-1a) recombinante
CA2342773A1 (en) * 1998-09-18 2000-03-30 Zymogenetics, Inc. Interferon-epsilon
WO2001079289A2 (en) * 2000-04-14 2001-10-25 Zymogenetics, Inc. Human interferon, zinf2

Also Published As

Publication number Publication date
AU2001267099A1 (en) 2001-12-24
US20020025304A1 (en) 2002-02-28
JP2004505021A (ja) 2004-02-19
NZ522849A (en) 2004-05-28
WO2001095929A2 (en) 2001-12-20
BG107370A (en) 2003-11-28
NO20025964D0 (no) 2002-12-12
WO2001095929A3 (en) 2002-10-10
CA2413077A1 (en) 2001-12-20
HUP0300787A2 (hu) 2003-07-28
PL359562A1 (en) 2004-08-23
NO20025964L (no) 2003-02-14
MXPA02012308A (es) 2003-04-25
CZ20024094A3 (cs) 2003-05-14
SI21080A (sl) 2003-06-30
BR0111852A (pt) 2003-05-20
EE200200693A (et) 2004-06-15
RU2003100517A (ru) 2004-06-27
SK17612002A3 (sk) 2003-08-05
KR20030009529A (ko) 2003-01-29
CN1436086A (zh) 2003-08-13
IL152996A0 (en) 2003-06-24
EP1289541A2 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
HK1026144A1 (en) Aryl ureas for the treatment of inflammatory or immunomodulatory diseases.
EP1033998A4 (en) METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
CA2184908A1 (en) Human osteoclast-derived cathepsin
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
DK0662827T3 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
GB9806632D0 (en) Peptide factor
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
LT2002123A (en) Novel interferon for the treatment of multiple sclerosis
DE69911401D1 (en) Immunoregulator
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
NO20020950L (no) Fremgangsmåte for fremstilling av peptider
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
HK1029937A1 (en) Use of phanquinone for the treatment of alzheimer s disease.
IL145722A0 (en) Pharmaceutical composition comprising growth hormone and interferon
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
ATE371737T1 (de) Proteaseresistente flint-analoge
DK0938329T3 (da) Immunogen TLP sammensætning
BG101846A (en) HUMAN DNase I VARIANTS
WO2000026362A3 (de) Proteine der stomatinfamilie und ihre verwendung als zielproteine für die schmerztherapie
CA2242562A1 (en) Human dnase resistant to actin inhibition